Oric Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2020-04-28

Reporting Person: Svennilson Peter (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-28	Common Stock	C	3500000	—	Acquired	3575000	Indirect
2020-04-28	Common Stock	C	625000	—	Acquired	4200000	Indirect
2020-04-28	Common Stock	C	416666	—	Acquired	4616666	Indirect
2020-04-28	Common Stock	C	151515	—	Acquired	4768181	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-28	Series A Preferred Stock	$	C	3500000	Disposed		Common Stock (3500000)	Indirect
2020-04-28	Series B Preferred Stock	$	C	625000	Disposed		Common Stock (625000)	Indirect
2020-04-28	Series C Preferred Stock	$	C	416666	Disposed		Common Stock (416666)	Indirect
2020-04-28	Series D Preferred Stock	$	C	151515	Disposed		Common Stock (151515)	Indirect

Footnotes

F1: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.

F2: The shares are held of record by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP. The Reporting Person is a Managing Partner of TCG II GP and may be deemed to share voting and investment power with respect to the shares reported herein. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any.